Assessing tissue damage in multiple sclerosis: A biomarker approach

Acta Neurologica Scandinavica

Volumn 130, Issue 2, 2014, Pages 81-89

  Burman, J ^a,b   Zetterberg, H ^c,d   Fransson, M ^a   Loskog, A Si ^a   Raininko, R ^a   Fagius, J ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Glial fibrillary acidic protein; Magnetic resonance imaging; Multiple sclerosis; Myelin basic protein; Neurofilament

Indexed keywords

BIOCHEMICAL MARKER; GADOLINIUM PENTETATE MEGLUMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; MYELIN BASIC PROTEIN; NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MBP PROTEIN, HUMAN; NEUROFILAMENT PROTEIN L;

ADULT; ARTICLE; ASTROCYTE; BRAIN; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE FIBER; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; SPINAL CORD; TISSUE INJURY; CASE CONTROL STUDY; PATHOLOGY; PROCEDURES;

ADULT; ASTROCYTES; BIOLOGICAL MARKERS; BRAIN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEINS; OLIGODENDROGLIA; SPINAL CORD;

EID: 84904721629     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12239     Document Type: Article

References (34)

1. Lublin F, Reingold S. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-11.
2. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770-82.
3. Petzold A, Michel P, Stock M, Schluep M. Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome. J Stroke Cerebrovasc Dis 2008;17:196-203.
4. Cohen S, Herndon R, McKhann G. Radioimmunoassay of myelin basic protein in spinal fluid. An index of active demyelination. N Engl J Med 1976;295:1455-7.
5. Whitaker J. Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with multiple sclerosis. Neurology 1977;27:911-20.
6. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747.
7. Lee M, Cleveland D. Neuronal intermediate filaments. Annu Rev Neurosci 1996;19:187-217.
8. Kuhle J, Malmestrom C, Axelsson M et al. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013;128:e33-6.
9. Lycke J, Karlsson J, Andersen O, Rosengren L. Neurofilament protein in cerebrospinal fluid - a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402-4.
10. Malmeström C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003;61:1720-5.
11. Norgren N, Sundström P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004;63:1586-90.
12. Teunissen C, Iacobaeus E, Khademi M et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72:1322-9.
13. Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287-92.
14. Gunnarsson M, Malmestrom C, Axelsson M et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011;69:83-9.
15. Eng L, Ghirnikar R, Lee Y. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 2000;25:1439-51.
16. Rosengren L, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients - relation to neurological deficit. J Neurol Sci 1995;133:61-5.
17. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75:208-16.
18. Lassmann H, Wekerle H. The pathology of multiple sclerosis. In: Compston A, Confavreux C, Lassman H, Mcdonald I, Miller D, Noseworthy J, Smith K, Wekerle H, eds. McAlpine's multiple sclerosis, 4th edn. London: Churchill Livingstone, 2005; 557-9.
19. Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
21. Rosengren L, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods 1994;51:197-204.
22. Salonen O, Autti T, Raininko R, Ylikoski A, Erkinjuntti T. MRI of the brain in neurologically healthy middle-aged and elderly individuals. Neuroradiology 1997;39:537-45.
23. Agren-Wilsson A, Lekman A, Sjöberg W et al. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand 2007;116:333-9.
24. Dziedzic T, Metz I, Dallenga T et al. Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. Brain Pathol 2010;20:976-85.
25. Frischer JM, Bramow S, Dal-Bianco A et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175-89.
26. Tourdias T, Roggerone S, Filippi M et al. Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology 2012;264:225-33.
27. Semra Y, Seidi O, Sharief M. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002;122:132-9.
28. Petzold A, Eikelenboom M, Gveric D et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002;125:1462-73.
29. Charcot J. Histologie de la sclérose en plaques. Paris: Gaz Hop, 1868.
30. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
31. Filippi M, Rovaris M, Capra R et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 1998;121:2011-20.
32. Fisniku LK, Brex PA, Altmann DR et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-17.
33. Rovaris M, Rocca MA, Barkhof F et al. Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. Mult Scler 2011;17:319-26.
34. Alpert J, Thygesen K, Antman E, Bassand J. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology: American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.